Has Stephen Toothaker, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,857 in general payments to Stephen Toothaker, MD across 647 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Toothaker, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Toothaker, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Toothaker, MD

Medical Oncology · Searcy, ARNPI 1033123195

Payments from drug & device makers

$18,857in general payments, 2019–2025

Across 647 payments — averaging $29.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$4K
Novartis$4K
G1 Therapeutics, Inc.$2K
AbbVie$1K
Pfizer$917
Merck$728
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	49	$3,611
Novartis	98	$3,547
G1 Therapeutics, Inc.	3	$1,534
AbbVie	22	$1,161
Pfizer	51	$917
Merck	43	$728
Johnson & Johnson(2 entities)	33	$670
Sanofi	16	$449
Seagen Inc.	22	$424
Amgen	25	$409
Daiichi Sankyo Inc.	18	$371
E.r. Squibb & Sons, L.L.C.	20	$333
GSK	14	$302
Incyte Corporation	16	$302
Bristol Myers Squibb	17	$298
Genentech USA, Inc.	14	$225
Eisai Inc.	11	$211
Gilead(2 entities)	11	$210
Novocure GmbH	1	$200
Lilly USA, LLC	9	$181
Athenex Pharmaceutical Division, LLC	1	$175
Pharmacyclics LLC, An Abbvie Company	10	$173
Ipsen Biopharmaceuticals, Inc	8	$166
Adaptive Biotechnologies Corporation	7	$125
Bayer	7	$125
Karyopharm Therapeutics Inc.	7	$125
Array Biopharma Inc	10	$114
Astellas Pharma US Inc	7	$114
Beigene USA, Inc.	6	$97
Coherus Oncology, Inc.	5	$92
Exelixis Inc.	6	$84
Genmab U.S., Inc.	4	$78
Servier Pharmaceuticals LLC	3	$68
Takeda Pharmaceuticals U.S.A., Inc.	4	$65
Jazz Pharmaceuticals Inc.	4	$57
EMD Serono, Inc.	4	$53
Geron Corporation	2	$50
Boehringer Ingelheim	3	$49
Tersera Therapeutics LLC	3	$48
Sun Pharmaceutical Industries Inc.	2	$48
Dova Pharmaceuticals	3	$46
Regeneron Healthcare Solutions, Inc.	2	$46
Syndax Pharmaceuticals, Inc.	2	$46
Rigel Pharmaceuticals, Inc.	3	$46
Tempus AI, Inc	2	$42
Taiho Oncology, Inc.	2	$42
AVEO Pharmaceuticals, Inc.	2	$41
Azurity Pharmaceuticals, Inc.	2	$39
Tolmar Pharmaceuticals, Inc.	2	$38
Epizyme, Inc.	3	$38
Sobi, Inc	2	$36
Pharmaessentia USA Corporation	2	$35
Clovis Oncology, Inc.	2	$32
Puma Biotechnology, Inc.	2	$31
Kyowa Kirin, Inc.	2	$29
Blueprint Medicines Corporation	1	$29
Organon	2	$24
Stemline Therapeutics Inc.	1	$18
Acrotech Biopharma Inc.	1	$17
ADC Therapeutics America, Inc.	1	$17

How this compares

$18,857 in reported general payments places this provider in the 70th percentile of 20 medical oncology providers in Arkansas.

See all medical oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024

$148,523

Medicare patients

333

Services billed

2,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Searcy

Ryan KochSearcy$15K
William RobertsonSearcy$4K
Muthu KumaranLittle Rock$413K
Cesar Gentille SanchezLittle Rock$117K
Marc MonteJonesboro$63K
Sunilkumar KakadiaHot Springs$37K
Ankur VarmaLittle Rock$23K
Zaki SammanFort Smith$16K
Kristen SagerMena$8K
Chen HuangHarrison$5K

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →